MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Thyroid Cancer Diagnosis and Treatment
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,440 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,440 works in the cohort · of 4,299,418page 13 of 29

Labels cover 6 of 1,440 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,440 of 1,440 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractgemma · no categorygpt · no categorymodels agree
426P A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg
Marcia S. Brose, Y. Panaseykin, Bhavana Konda, Christelle de la Fouchardière, Brett Hughes, Andrew G. Gianoukakis +7 more
2020· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
13
citations
fundno affunlabeled
Thyroid Cancer
Leonard Wartofsky, Douglas Van Nostrand
2006· book· en· Humana Press eBooks· Medicine
machine prediction:candidate · noneconsensus · none
13
citations
affvenueunlabeled
Genetic Events in the Evolution of Thyroid Cancer
Jeremy L. Freeman, Camilla Carroll, L. Sylvia, Shereen Ezzat
2002· article· en· The Journal of Otolaryngology· Medicine
machine prediction:candidate · noneconsensus · none
13
citations
affno abstractunlabeled
Molecular pathology of thyroid cancer
Clarissa A. Cassol, L. Sylvia
2011· article· en· Diagnostic histopathology· Medicine
machine prediction:candidate · noneconsensus · none
12
citations
afffundunlabeled
Local molecular analysis of indeterminate thyroid nodules
M. S. S. Gill, Smriti Nayan, Linda Kocovski, Jean‐Claude Cutz, Stuart Archibald, Bernard S. Jackson +2 more
2015· article· en· Journal of Otolaryngology - Head and Neck Surgery· Medicine
machine prediction:candidate · noneconsensus · none
12
citations

How this was built: Screen · Findings · About